Treatment of melanoma by reduction in clusterin levels
CA 2494764 C · Owner: The University Of British Columbia · Inventors: Jansen, Burkhard; Gleave, Martin E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Treatment of melanoma is achieved through reduction in the effective amount of clusterin in melanoma cells. Thus, in accordance with one aspect of the invention, there is provided a method for treatment of melanoma in a mammalian subject, preferably a human, comprising the step of administering to the subject a therapeutic agent effective to reduce the effective amount of clusterin in the melanoma cells. The therapeutic agent may be for example, an , antisense ODN or small inhibitory RNA (siRNA) compound targeted to clusterin. The present invention also provides a method for regulating expression of bclxL in a subject or cell line comprising administering to the subject or cell line …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 21, 2003 and granted April 23, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 21, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 21, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.